FV-100
外观
FV-100 | |
---|---|
![]() | |
IUPAC名 3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one | |
系统名 3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one | |
别名 | Cf1743 |
识别 | |
CAS号 | 956483-02-6 ![]() |
PubChem | 493485 |
ChemSpider | 431897 |
SMILES |
|
性质 | |
化学式 | C22H26N2O5 |
摩尔质量 | 398.45 g·mol−1 |
若非注明,所有数据均出自标准状态(25 ℃,100 kPa)下。 |
FV-100(也称为Cf1743)是一种含氮有机化合物,分子式C
22H
26N
2O
5,属于核苷酸类似物[1],可作为抗病毒药物[2],用于治疗带状疱疹[3]。
参考文献
[编辑]- ^ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
- ^ McGuigan, Christopher; Balzarini, Jan. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. Journal of Antimicrobial Chemotherapy. 2009, 64 (4): 671–673. PMID 19679595. doi:10.1093/jac/dkp294
.
- ^ Tyring, SK; Lee, P; Hill GT, Jr; Silverfield, JC; Moore, AY; Matkovits, T; Sullivan-Bolyai, J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial.. Journal of medical virology. 2017-07, 89 (7): 1255–1264. PMID 27943311. doi:10.1002/jmv.24750.